F-1/A: Universe Pharmaceuticals Seeks $25 Million in Best Efforts Offering Amid Regulatory Scrutiny

Universe Pharmaceuticals is launching a best efforts self-underwritten public offering of up to 20,000,000 ordinary shares at $1.25 per share to raise capital amid risks associated with operating in China and regulatory uncertainties.

Summary

• Universe Pharmaceuticals INC, a Cayman Islands holding company with operations in China, is offering up to 20,000,000 ordinary shares at a price of $1.25 per share in a best efforts, self-underwritten public offering.
• The company aims to raise approximately $25 million, which will be used for expanding production capacity (55%), advertising and branding (30%), and general corporate purposes (15%).
• The offering is expected to close around June 15, 2024, and will terminate by September 30, 2024, if all shares are not sold.
• There is no minimum offering amount required to close, which means the company may receive significantly less than the targeted $25 million.
• The company's ordinary shares are listed on the Nasdaq Capital Market under the symbol UPC, with the last reported sale price on May 13, 2024, at $2.335 per share.
• Universe Pharmaceuticals operates in China through its subsidiary, Jiangxi Universe Pharmaceuticals Co., Ltd., focusing on the manufacturing, marketing, and sales of Traditional Chinese Medicine Derivatives (TCMD) products.
• The company faces legal and operational risks associated with having the majority of its operations in China, including potential intervention from the PRC government and uncertainties in the Chinese legal system.
• The company must file with the CSRC within three days after the offering is completed, in accordance with the Trial Measures.
• The company's auditor, YCM CPA INC., is headquartered in California and has been inspected by the PCAOB.
• The company has not paid dividends in the past and does not expect to pay any in the foreseeable future, intending to reinvest earnings into business expansion.
• For the years ended September 30, 2023, 2022 and 2021, we distributed around 2,239, 2,785 and 2,766 types of third-party products, respectively.
• The revenues from selling the PRC operating entities own products decreased from $29,559,286 for the fiscal year ended September 30, 2021 to $23,988,177 for the fiscal year ended September 30, 2022 due to our inability to timely fulfill the orders of our customer in 2022 due to the resurgence of COVID-19 cases in China, and further decreased to $18,572,658 for the fiscal year ended September 30, 2023, as we changed our pricing strategy and decreased selling price of our TCMD products to increase sales volume and market share.
• The revenues from distributing and selling third-party products decreased from $18,422,745 for the fiscal year ended September 30, 2021 to $16,154,974 in the fiscal year ended September 30, 2022 due to a decrease in the weighted average selling price caused by a change in product mix, and further decreased to $13,736,077 for the fiscal year ended September 30, 2023 due to decreased sales volume and negative impact from foreign currency fluctuation.
• Our net income was $11,319,952 for the fiscal year ended September 30, 2021, net loss was $8,736,566 for the fiscal year ended September 30, 2022 due to a decrease in our revenue and increase in our selling expense, and our net loss was $6,163,061 for the fiscal year ended September 30, 2023 due to the decrease in our revenue and increase in cost of revenue.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is pursuing growth initiatives through a capital raise, it faces significant risks related to its operations in China and has experienced recent financial losses. The 'best efforts' nature of the offering and the potential for dilution add to the uncertainty.

Positives

• The company has identified specific uses for the capital raised, including expanding production capacity and increasing advertising efforts.
• The company's auditor, YCM CPA INC., is headquartered in California and has been inspected by the PCAOB.
• The company has registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the NMPA), and we currently produce 13 varieties of TCMD products, which are sold in approximately 261 cities of 30 provinces in China.

Negatives

• The offering is on a 'best efforts' basis, meaning there's no guarantee the company will raise the full $25 million.
• The company operates in China, which carries significant regulatory and political risks.
• The company has experienced net losses in recent fiscal years.
• The company has not paid dividends in the past and does not expect to pay any in the foreseeable future, intending to reinvest earnings into business expansion.
• The offering price of $1.25 is significantly lower than the last reported sale price of $2.335 on May 13, 2024.

Risks

• The company's operations in China are subject to intervention and influence by the PRC government.
• Changes in Chinese laws and regulations could adversely affect the company's business and financial condition.
• The company's ordinary shares may be delisted if the PCAOB is unable to inspect the company's auditors.
• Failure to comply with cybersecurity and data privacy laws could materially harm the company.
• The company may not be able to obtain required approvals from the China Securities Regulatory Commission (CSRC) for the offering.
• The company faces risks related to its supply chain, competition, and ability to increase production capacity.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• The offering price of the shares offered hereby is substantially higher than our net tangible book value per share, you will experience immediate and substantial dilution.

Future Outlook

The company intends to use the net proceeds from this offering for expanding our production capacity and increasing the number of our production lines, for advertising and branding campaigns, and for other general corporate purposes, including working capital, operating expenses, and capital expenditures.

Industry Context

The company operates in the Traditional Chinese Medicine (TCM) market, targeting the elderly population in China. This market is influenced by factors such as the aging population, government policies, and consumer preferences for TCM products.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific financial benchmarks or competitor data, it's difficult to assess Universe Pharmaceuticals' performance against industry peers.

Stakeholder Impact

• Shareholders face potential dilution and risks associated with the company's operations in China.
• Employees may benefit from the company's expansion plans, but also face risks related to the company's financial performance and regulatory environment.
• Customers may benefit from increased production capacity and improved products, but also face risks related to the company's financial stability.
• Suppliers and creditors face risks related to the company's financial performance and ability to meet its obligations.

Next Steps

• Complete the offering and secure the necessary funding.
• File with the CSRC within three days after the offering is completed.
• Implement the planned use of proceeds, focusing on expanding production capacity and advertising efforts.
• Monitor and manage the risks associated with operating in China, including regulatory changes and potential government intervention.

Key Dates

Keywords

pharmaceuticals, offering, TCMD, China, securities, regulatory, Universe